Moreover, we explored the correlation between PRMT2 expression and 5-year overall survival (OS) and 5-year disease-free survival (DFS) in patients with RCC using Kaplan–Meier survival analysis and log-rank tests. Here, PRMT2 is linked to renal cell adenocarcinoma.